Abstract 116: A novel murine model for interrogating tumor heterogeneity in non-small cell lung cancer

Michael S. Oh,Jensen W. Abascal,Linh M. Tran,Ramin Salehi-Rad,Raymond J. Lim,Bitta P. Kahangi,William P. Crosson,Edgar Perez Reyes,Jacey Yang,Cara Yeah,Kostyantyn Krysan,Bin Liu,Steven M. Dubinett

DOI: https://doi.org/10.1158/1538-7445.am2023-116

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract Treatment for non-small cell lung cancer (NSCLC) has been transformed by the use of immune checkpoint inhibitors (ICIs), which promote the ability of the immune system to attack cancer cells. Resistance to these therapies thus represents a major barrier to effectively treating patients with NSCLC. Tumor heterogeneity has been identified as an important factor that may mediate ICI resistance, and prior analyses of NSCLC tumors have accordingly shown that greater tumor heterogeneity is correlated with diminished response to ICIs. However, the exact mechanisms of heterogeneity-mediated resistance remain unclear, and there exist a lack of models for studying the impact of tumor heterogeneity on therapeutic efficacy in NSCLC. To address this issue, we have developed a novel murine model of NSCLC that incorporates a system of clonal cell lines to precisely modulate tumor heterogeneity. Specifically, we isolated single tumor cells from a murine NSCLC cell line harboring 3 common driver mutations (KrasG12DTp53+/−Lkb1−/−, or “KPL”). We additionally isolated single cells after mutagenizing the KPL line with the alkylating agent N-methyl-N-nitrosourea, in order to obtain clones that better reflect the higher tumor mutation burden often seen in NSCLC. Clonal cell lines were derived from these single cells and then analyzed using whole exome sequencing to verify clonality and characterize their mutational profile. Phylogenetic analysis of mutations yielded categorization of these clones into 5 clusters. Clones within the same cluster demonstrated comparable in vivo growth kinetics and similar response to anti-PD-1 immunotherapy. Combinations of these clones can be used to recapitulate various levels of heterogeneity and to form tumors with differing responses to PD-1 inhibition. Our results validate this system of clonal cell lines as a model of NSCLC that can modify multiple aspects of tumor heterogeneity and thus provide insights into the effects of tumor heterogeneity on ICIs and other immunotherapies. Citation Format: Michael S. Oh, Jensen W. Abascal, Linh M. Tran, Ramin Salehi-Rad, Raymond J. Lim, Bitta P. Kahangi, William P. Crosson, Edgar Perez Reyes, Jacey Yang, Cara Yeah, Kostyantyn Krysan, Bin Liu, Steven M. Dubinett. A novel murine model for interrogating tumor heterogeneity in non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 116.

oncology